Gossamer Bio slides after bowel disease drug fails study

Gossamer Bio

25/04/2022 13:08

** Drug developer's shares  GOSS.O  fall 20.1% to $7.1
premarket
    ** Co says its experimental treatment for ulcerative
colitis, an inflammatory bowel disease, failed to meet the main
or secondary goals of a mid-stage trial  urn:newsml:reuters.com:*:nBw3Drc9Fa
    ** GOSS to terminate the trial due to a lack of treatment
benefit
    ** There was no significant difference in the number of
patients who achieved disease remission, regardless of whether
they took the drug or placebo
    ** GOSS shares down ~22% this year, after rising nearly 17%
in 2021 

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))